This study is a multi-center, randomized prospective trial with a 6-month follow up. A newly developed treatment and education module will be tested compared to a waiting-list control group. The module covers the topic "diabetes and partnership". Primary outcome variable is diabetes-specific empowerment regarding diabetes and partnership. Secondary outcome variables are: diabetes-related distress, health-related quality of life, depressive symptoms, self-care behavior, and glycemic control.
The module consists of one lesson (duration: 90 minutes). The module is derived from the empowerment approach and is based on the previously evaluated education and treatment program for type 1 diabetes: PRIMAS (NCT01220557). The module is designed as a group session held by a trained diabetes educator. Patients are randomized either to the immediate participation in the module or to the control group. Control group is a waiting-list control group. Patients in this waiting-list control group get the education after the completion of the 6-month follow-up.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
201
Based on the treatment and education programme PRIMAS a problem-specific education module regarding "Diabetes and Partnership" was created. The module covers specific and detailed aspects of the topic "partnership" such as dealing with hypoglycemia, late complications, and talking about diabetes in a relationship. With this module, a more comprehensive education of patients with specific interest in these topics is possible.
Research Institute of the Diabetes Academy Mergentheim (FIDAM)
Bad Mergentheim, Germany
Zentrum für Diabetologie Bergedorf
Hamburg, Germany
Diabeteszentrum Ludwigsburg
Ludwigsburg, Germany
Diabetologische Schwerpunktpraxis Neuss
Neuss, Germany
Change from baseline in diabetes-specific empowerment on the adapted Diabetes Empowerment Scale at the 2-week and 6-month follow-up
The Diabetes Empowerment Scale was specifically adjusted to cover "partnership" issues. Psychometric criteria for these adjusted scale were evaluated in an independent study
Time frame: Baseline, 2-week follow-up , 6-month follow-up
Change from baseline in problem-specific distress on the adapted Problem Areas in Diabetes (PAID) Scale at the 2-week and 6-month follow-up
The PAID scale was specifically adapted to cover "partnership". Psychometric quality was assessed in an independent study
Time frame: baseline, 2-week follow-up, 6-month follow-up
Change from baseline in glycemic control (HbA1c) at the 2-week and 6-month follow-up
HbA1c will be analyzed in a central laboratory.
Time frame: baseline, 2-week follow-up, 6-month follow-up
Change from baseline in health-related quality of life on the EQ-5D at the 2-week and 6-month follow-up
Time frame: baseline, 2-week follow-up, 6-month follow-up
Change from baseline in quality of life on the WHO-5 at the 2-week and 6-month follow-up
Time frame: baseline, 2-week follow-up, 6-month follow-up
Change from baseline in self-efficacy on the General Self-Efficacy Scale (GSE) the 2-week and 6-month follow-up
Time frame: baseline, 2-week follow-up, 6-month follow-up
Change from baseline in general diabetes-distress at the 2-week and 6-month follow-up
Time frame: baseline, 2-week follow-up, 6-month follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change from baseline in depressive symptoms on the CES-D at the 2-week and 6-month follow-up
Time frame: baseline, 2-week follow-up, 6-month follow-up